Chiesi takes on Seretide and other lung drugs with Trimbow.
FDA rejects Hikma drug, regulator has “major” issue with Mylan’s rival.
Encouraging results will support growth of its next generation respiratory treatment
Big projects are priority as threat from generic Advair looms.
Building not operational until 2019, says CEO
UK biotech to focus on respiratory drugs after house dust mite therapy fails.
BI boosted by new diabetes and respiratory drugs.